Filing Overview
Registrant: Bull Horn Holdings Corp. (the request identifies Z Squared Inc., but the filing names Bull Horn Holdings Corp.)
Form 8-K date: October 26, 2022. The report covers shareholder approval of the proposed domestication and business combination with Coeptis Therapeutics, Inc.
Business Context and Transaction
Bull Horn held a special shareholder meeting concerning its merger agreement with Coeptis Therapeutics. Under the proposed transaction, Bull Horn would domesticate from the British Virgin Islands to Delaware, and a wholly owned merger subsidiary would merge with Coeptis, with Coeptis surviving as a wholly owned subsidiary.
Upon closing, the combined company was expected to be named Coeptis Therapeutics Holdings, Inc. The filing states that the transaction was expected to close promptly after satisfaction or waiver of the remaining closing conditions.
Financial and Capitalization Matters
- Approximately 2,869,654 ordinary shares, or approximately 88.5% of Bull Horn’s outstanding public shares, were submitted for redemption.
- Approximately $3.8 million was expected to remain in Bull Horn’s trust account following redemptions.
- The filing does not provide revenue, net income, operating cash flow, margins, debt balances, or detailed liquidity metrics for the reporting period.
- The filing cautions that substantial redemptions could leave the combined company with limited funds to finance its business plans.
Shareholder Vote and Material Changes
A total of 3,121,288 shares were voted in person or by proxy, and all proposals were approved.
| Proposal | For | Against | Abstentions |
|---|---|---|---|
| Domestication | 2,895,594 | 225,694 | 0 |
| Business combination | 2,895,589 | 225,699 | 0 |
| 2022 equity incentive plan | 2,805,064 | 225,704 | 90,520 |
| Charter amendments | Approved | Approximately 225,694–225,699 | 0–2 |
The charter amendments included declassifying the board, establishing director-removal provisions, adopting federal and Delaware forum-selection provisions, specifying amendment procedures, revising indemnification provisions, and removing blank-check-company provisions. Shareholders also elected seven directors to serve through the 2023 annual meeting and until successors are elected.
The adjournment proposal was not presented because the other proposals received sufficient approval.
Outlook, Risks, and Unusual Items
- Completion remained subject to satisfaction or waiver of the remaining conditions in the merger agreement; shareholder approval alone did not assure closing.
- Key risks include termination or failure to complete the transaction, inability to maintain Nasdaq listing, substantial redemptions and limited post-closing funding, transaction-related disruption and costs, and failure to realize anticipated benefits.
- Coeptis’ products in development may fail clinical trials or not receive approval from the FDA or other regulators.
- Additional risks include competition, growth-management and employee-retention challenges, changes in law or regulation, broader economic and business conditions, and COVID-19 effects.
- The filing contains forward-looking statements regarding transaction timing, performance, and anticipated financial impacts; actual results may differ materially.
Investor Verification Points
- Verify whether the domestication and business combination were subsequently completed and the effective closing date.
- Confirm the final number of redeemed shares and the cash ultimately available at closing.
- Review subsequent filings for the combined company’s revenue, cash burn, debt, financing needs, and going-concern or liquidity disclosures.
- Confirm the post-transaction Nasdaq listing, corporate name, ticker symbols, and final ownership structure.
- Review the merger agreement, proxy statement, and risk factors for remaining closing conditions, dilution, regulatory risks, and product-development milestones.